Synspira Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Synspira's estimated annual revenue is currently $1.6M per year.(i)
  • Synspira's estimated revenue per employee is $155,000

Employee Data

  • Synspira has 10 Employees.(i)
  • Synspira grew their employee count by -41% last year.

Synspira's People

NameTitleEmail/Phone
1
Executive Director Program and Data AnalyticsReveal Email/Phone
2
ConsultantReveal Email/Phone
3
Quality Assurance, Technical Writing Support ConsultantReveal Email/Phone
4
Quality Systems ConsultantReveal Email/Phone
5
Analytical and Process Development Co-OpReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Synspira?

Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases. Inspired by patients, Synspira is focused on developing a rationally designed portfolio of products that can make a life-changing impact and improve the quality of life of patients. Synspira is working to advance two novel products (SNSP113 and SNSP003) intended to provide better clinical outcomes and reduce treatment burden in pulmonary disease as well as malabsorption syndromes and exocrine pancreatic insufficiency. SNSP113, Synspira's lead product, is in a Phase 2 clinical study in people with cystic fibrosis. Synspira is a privately held company headquartered in Framingham, MA.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

-41%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M10-23%N/A
#2
$1.3M10-74%N/A
#3
$1.6M100%N/A
#4
$1.7M1220%$20.9M
#5
$1.2M12-69%N/A